Zobrazeno 1 - 10
of 380
pro vyhledávání: '"Mario, Sznol"'
Autor:
Xinxing Li, Tao Liu, Antonella Bacchiocchi, Mengxing Li, Wen Cheng, Tobias Wittkop, Fernando L Mendez, Yingyu Wang, Paul Tang, Qianqian Yao, Marcus W Bosenberg, Mario Sznol, Qin Yan, Malek Faham, Li Weng, Ruth Halaban, Hai Jin, Zhiqian Hu
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 9, Pp 2188-2209 (2024)
Abstract While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technolog
Externí odkaz:
https://doaj.org/article/61e8893361234a0aaada760b5863e691
Autor:
Mark Voskoboynik, Justin Moser, Mario Sznol, Amita Patnaik, Amanda Enstrom, Diwakar Davar, Michael Millward, Rachel E Sanborn, Meredith McKean, Justin F Gainor, Nehal Lakhani, Heidi LeBlanc, Stanford L Peng, Heather Thomas, Lori Blanchfield, Michael J Chisamore, Allison Naumovski, Ludimila Cavalcante, Jaspreet S Grewal, Ajita Narayan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Davoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain designed to mediate programmed death-ligand 1 (PD-L1)-dependent CD28 co-stimulation while inhibiting the PD-L1 and cytotoxic T-lymphocyte-associated antigen 4
Externí odkaz:
https://doaj.org/article/09d04456db2341698a183766d4d11533
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic
Externí odkaz:
https://doaj.org/article/411006a42ab147bf8691be7123885805
Autor:
Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu, Harriet M. Kluger
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-15 (2023)
Abstract Background Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpos
Externí odkaz:
https://doaj.org/article/4fa1a648e79343f59ea5d04accc2e62b
Autor:
Alexander E. Frey, Daniel M. Kerekes, Sajid A. Khan, Thuy T. Tran, Harriet M. Kluger, James E. Clune, Stephan Ariyan, Mario Sznol, Jeffrey J. Ishizuka, Kelly L. Olino
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundImmunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on cl
Externí odkaz:
https://doaj.org/article/ddc0f0206d7a46fda9e76b144e93694b
Autor:
Mario Sznol, Adil Daud, Scott M Turner, Chris N Barnes, Susan Owen, Eric A Lefebvre, Hardean E Achneck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b58dd5cb21174445b278c917f39dc879
Autor:
Mario Sznol, Harriet Kluger, Michael Hurwitz, Adebowale Adeniran, Peter Humphrey, David Braun, Lena Wirth, Soki Kashima, Hanna Soulati, Katrine Madsen, Katherine Sadak, Patrick Kenney
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ae26b4bac3ae4c5685120cdd4801bbc5
Autor:
Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c9d6a589d3ec4c688bdb430c28cf8a3d
Autor:
Renee N Donahue, Jeffrey Schlom, James L Gulley, Mario Sznol, Andreas Schroeder, Julius Strauss, Luc Dirix, Michele Maio, Frank Beier, Alain Ravaud, Jean-Laurent Deville, Marco Maruzzo, XiaoZhe Wang, Yulia Vugmeyster, Sarah Chennoufi, Yo-Ting Tsai, Russell K Pachynski, Theodore S Gourdin, Joerg Seebeck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background In preclinical studies, combining M9241 (a novel immunocytokine containing interleukin (IL)-12 heterodimers) with avelumab (anti-programmed death ligand 1 antibody) resulted in additive or synergistic antitumor effects. We report dose-esca
Externí odkaz:
https://doaj.org/article/b7193fb23a874fb9822f7bc391a3e7f9
Autor:
Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune, Kelly Olino, Laxmi Parida, Joerg Nikolaus, Meiling Zhang, Shuang Zhao, Yan Wang, Gang Huang, Miaojian Wan, Xianan Li, Jian Cao, Qin Yan, Xiang Chen, Aaron M. Newman, Ruth Halaban
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Despite acral melanoma being the most common melanoma subtype in non-White individuals, its molecular drivers remain unknown. Here, the authors integrate genomic and clinical data from 104 patients and identify late-arising focal amplifications of ch
Externí odkaz:
https://doaj.org/article/b66dfca16a5a4cbdb29e51d65dceaf25